Boehringer Ingelheim to Enter Biosimilars Business

Boehringer Ingelheim (Ingelheim, Germany) says it will establish a new separate business for the development and commercialization of biosimilars. Biosimilars are approved versions of innovator biopharmaceutical products introduced after patent expiry. “We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines,” says Wolfram Carius, member of the board of managing directors and responsible for operations at Boehringer Ingelheim. The company will leverage its...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers